Dawne Hershberger
Family · Abbeville, SCNPI 1871572107
Payments from drug & device makers
Across 60 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$148
- Dexcom, Inc.$103
- Otsuka America Pharmaceutical, Inc.$99
- UCB, Inc.$75
- Amgen$64
- Abbott$58
- plus $506 from 20 others
What the payments were for
- Food & beverage$1,053100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $148 |
| Dexcom, Inc. | 8 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| UCB, Inc. | 2 | $75 |
| Amgen | 4 | $64 |
| Abbott | 4 | $58 |
| Argenx US, Inc. | 2 | $57 |
| Novartis | 3 | $52 |
| Abiomed | 2 | $41 |
| Johnson & Johnson | 3 | $41 |
| Nestle Healthcare Nutrition Inc. | 3 | $38 |
| Medtronic | 1 | $32 |
| Pfizer | 2 | $31 |
| Eisai Inc. | 1 | $27 |
| Vital Connect, Inc | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Organon | 1 | $4 |
How this compares
$1,053 in reported general payments places this provider in the 65th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 68 | $35,961 |
| MounjaroTirzepatide | 31 | $31,283 |
| OzempicSemaglutide | 17 | $24,945 |
| EliquisApixaban | 20 | $18,876 |
| Potassium Chloride | 166 | $4,664 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,480 |
| Fentanyl | 16 | $2,197 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $2,001 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 64 | $1,553 |
| RivastigmineRivastigmine Tartrate | 19 | $1,521 |
| Levothyroxine Sodium | 136 | $1,432 |
| Losartan Potassium | 108 | $1,427 |
| Omeprazole | 67 | $1,340 |
| Rosuvastatin Calcium | 58 | $1,328 |
| Gabapentin | 92 | $1,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $14 | $35,96168 claims |
| Novo NordiskOzempic | $14 | $24,94517 claims |
| PfizerEliquis | $31 | $18,87620 claims |
| AstraZenecaSymbicort | $16 | $2,48011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,248 family providers in South Carolina.
Other family in Abbeville
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.